FRANKLIN LAKES, N.J., Feb. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Lanesha Minnix has been named executive vice president and general counsel for the company, effective March 16.

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.

The company reported sales of $5.25 billion, slightly above the consensus of $5.15 billion.

FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").

Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript

BDX posts an earnings beat with revenue growth and expanding margins in first-quarter fiscal 2026 quarter, though adjusted profit declined year over year.

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 250 points on Monday.

Medical device maker Becton Dickinson cut its profit forecast for fiscal year 2026 on Monday, adjusting its outlook to account for the separation and sale of its biosciences and diagnostics unit to lab equipment manufacturer Waters.

Becton Dickinson (BDX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.82 per share. This compares to earnings of $3.43 per share a year ago.

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE: WAT).